At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 554 enrolled
Drug / intervention
ATH-1017 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
In Brief
A Phase 3 clinical trial evaluating ATH-1017 and Placebo for Alzheimer Disease and Dementia of Alzheimer Type. Completed, enrolled 554 participants across 1 site.
Detailed Summary
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Dementia of Alzheimer Type
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartSep 2020
Primary CompletionJul 2024
TodayJul 2026
First PostedJul 28, 2020
Enrollment StartSep 28, 2020
Primary CompletionJul 15, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.9 years ago
Interventions
ATH-1017drug
Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Placebodrug
Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe